home / stock / cntb / cntb news

CNTB News and Press, Connect Biopharma Holdings Limited From 07/21/25

Stock Information
Company Name: Connect Biopharma Holdings Limited
Stock Symbol: CNTB
Market: NASDAQ
Website: connectbiopharm.com
Menu
CNTB CNTB Quote CNTB Short CNTB News CNTB Articles CNTB Message Board
Get CNTB Alerts

News, Short Squeeze, Breakout and More Instantly...
CNTB - Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced th...
CNTB - Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory di...

CNTB - Connect Biopharma regains Nasdaq compliance on minimum bid price

2025-07-17 09:41:59 ET More on Connect Biopharma Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Biopharma Read the full article on Seeking Alpha For further det...

CNTB - Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced it...
CNTB - Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory di...

CNTB - Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports ongoi...

CNTB - Connect Biopharma files $300M mixed securities shelf

2025-06-10 16:44:28 ET More on Connect Biopharma Connect Biopharma receives Nasdaq non-compliance notice Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for Connect Biopharma Financial information for Connect Biopharma ...
CNTB - Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary ...

CNTB - Connect Biopharma to Present at Two Upcoming Investor Conferences in June

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary d...

CNTB - Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which...
Previous 10 Next 10